Clinical Trials Using Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230
Clinical trials are research studies that involve people. The clinical trials on this list are studying Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
Location: 8 locations
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
Location: 6 locations
A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer
The primary objective of this study is to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who have previously received anti-PD-(L)1 therapy but who have not achieved a CR.
Location: 3 locations